Douglas D. Fang

An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED

Wei Qi, Kehao Zhao, Justin Gu et al. · Nature Chemical Biology · 2017 · 313 citations · Full text

Signal Transduction, Signaling Pathway, Cell Regulation +7

Expansion of CD133+ colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery

Douglas D. Fang, Y J Kim, C N Lee et al. · British Journal of Cancer · 2010 · 149 citations · Full text

MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment

Douglas D. Fang, Qiuqiong Tang, Yanhui Kong et al. · Journal for ImmunoTherapy of Cancer · 2019 · 146 citations · Full text

Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy

Ying Huang, Jeff Zhang, Zhengtian Yu et al. · Journal of Medicinal Chemistry · 2017 · 100 citations · Full text

HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib

Douglas D. Fang, Bin Zhang, Qingyang Gu et al. · Journal of Thoracic Oncology · 2014 · 95 citations · Full text

Medicinal Chemistry, Receptor Tyrosine Kinase, Systems Biology +4